Formalized prediction of clinically significant prostate cancer: Is it possible?

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 349-354

  Nguyen, Carvell T ^a   Kattan, Michael W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

prediction model; prostate cancer; prostatic neoplasms; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CLINICAL ASSESSMENT; HIGH RISK POPULATION; HUMAN; NOMOGRAM; PREDICTION; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

DELIVERY OF HEALTH CARE; DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENTINEL SURVEILLANCE; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84860858228     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.140     Document Type: Review

References (44)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954. (Pubitemid 23244733)
2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984. (Pubitemid 40638368)
3. Horner MJ, Ries LA, Krapcho M, Neyman N, Aminou R, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
4. General Information about Prostate Cancer. Bethesda, MD: National Cancer Institute; 2011.
5. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, ChiaDet al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
7. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2010; 101: 1325-1329.
8. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374. (Pubitemid 24037911)
9. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-2005. (Pubitemid 39425375)
10. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C et al. The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010; 58: 90-95.
11. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008; 54: 1306-1313.
12. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 2010; 105: 1526-1530.
13. Oon SF, Watson RW, O'Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int 2011; 108: 518-525.
14. Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: An analysis of pathologic features. Cancer 2008; 113: 2068-2072.
15. Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology 2002; 60: 666-669. (Pubitemid 35246455)
16. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: Preoperative application in prostate cancer. Curr Opin Urol 2003; 13: 111-116. (Pubitemid 36288341)
17. Terrin N, Schmid CH, Griffith JL, D'Agostino RB, Selker HP. External validity of predictive models: A comparison of logistic regression, classification trees, and neural networks. J Clin Epidemiol 2003; 56: 721-729. (Pubitemid 37040807)
18. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12: 6663-6676. (Pubitemid 44876834)
19. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: Results from medical data sets. Cancer 2001; 91 (8 Suppl): 1636-1642. (Pubitemid 32319240)
20. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352-3359.
21. Bauer JJ, Connelly RR, Seterhenn IA, Deausen J, Srivastava S et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159: 929-933. (Pubitemid 28106559)
22. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-138.
23. Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-Tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007; 99: 794-800. (Pubitemid 46439569)
24. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002; 7: 141-146.
25. KattanMW, Eastham JA, Wheeler TM, Maru N, Scardino PT et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-1797. (Pubitemid 37254930)
26. Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: Efficacy in contemporary urological practice. J Urol 2008; 180: 150-4; discussion 154.
27. Chun FK, Haese A, Ahyai SA, Walz J, Suardi N et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008; 113: 701-709.
28. Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112: 69-74.
29. Kattan MW. Factors affecting the accuracy of prediction models limit the comparison of rival prediction models when applied to separate data sets. Eur Urol 2011; 59: 566-567.
30. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
31. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 2008; 79: 1804-9; discussion 1809-1810.
32. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW et al. EPCA-2: A highly specific serum marker for prostate cancer. Urology 2007; 69: 714-720. (Pubitemid 46574950)
33. D'Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out. J Clin Oncol 1996; 14: 304-315.
34. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-1669. (Pubitemid 34240696)
35. Hardie C, Parker C, Norman A, Eeles R, Horwich A et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956-960. (Pubitemid 40655686)
36. Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol 2005; 23: 8165-8169. (Pubitemid 46211550)
37. Roemeling S, Roobol MJ, Kattan MW, van Der Kwast TH, Steyerberg EW et al. Nomogram use for the prediction of indolent prostate cancer: Impact on screendetected populations. Cancer 2007; 110: 2218-2221. (Pubitemid 350100743)
38. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003; 170 (4 Pt 1): 1203-1208. (Pubitemid 37108113)
39. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-1803. (Pubitemid 37254931)
40. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM et al. Predicting the presence and side of extracapsular extension: A nomogram for staging prostate cancer. J Urol 2004; 171: 1844-9; discussion 1849. (Pubitemid 38501019)
41. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006; 49: 820-826.
42. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT et al. Prediction of organconfined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238: 597-603. (Pubitemid 43134372)
43. Briganti A, Gallina A, Suardi N, Chun FK, Walz J et al. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int 2008; 101: 556-560. (Pubitemid 351199277)
44. Kattan MW. A nomogram for predicting 10-year life expectancy in men with prostate cancer after definitive therapy. Nat Clin Pract Urol 2008; 5: 138-139.(Pubitemid 351377146)